Preventing and Managing Resistance in the Clinical Setting

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue SUPPL. 2, 2003, Pages

  Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Partners AIDS Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 0242331228     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200310012-00002     Document Type: Review

References (24)

1. Little SJ, Holte S, Routy J-P, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-94.
2. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288;181-8.
3. st Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract LB-17]. Chicago, IL, December 16-19, 2001.
4. Hirsch MS, Brun-Vézinet, F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-28.
5. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR 2002;51(RR-7):1-64.
6. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001;15:309-20.
7. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002;18:825-34.
8. Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin Infect Dis 2003;36:373-7.
9. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
10. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002;16:2175-82.
11. Bangsberg DR, Kagay CR, Porco T, et al. Modelling the relationship between adherence and accumulation of protease inhibitor drug-resistance mutations based on objectively measured adherence and empirically derived relationships [abstract 160]. Presented at the XI International HIV Drug Resistance Workshop, Seville, Spain, July 2-5, 2002.
12. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug-resistance mutations in HIV-1. Topics HIV Med 2003;11:92-6.
13. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM [abstract 4481]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001.
14. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000;283:229-34.
15. Rusconi S, De Pasquale MP, Milazzo L, et al. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther 1998;3:203-7.
16. Kempf D, King M, Bauer E, et al. Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonavir or nelfinavir as initial therapy [abstract 600]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
17. Holder DJ, Condra JH, Schleif WA, et al. Virologic failure during drug combination therapy with CRIXIVAN and RT inhibitors is often associated with expression of resistance-associated mutations in RT only [abtract 492]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4, 2000.
18. Vavro C, McCarty D, Shortino D, et al. Genotypic analysis of HIV-1 from subjects experiencing virologic breakthrough while taking 3TC QD vs 3TC BID, EFV and ZDV [abstract H-2052]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
19. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir/ritonavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003;17:955-61.
20. Elston R, Randell S, Myers R, et al. Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance [abstract 465]. Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001.
21. King M, Bernstein B, Cernohous P, et al. Impact of baseline CD4 cell count and viral load on durability of virologic response through 96 weeks for lopinavir/ritonavir and nelfinavir in a phase III clinical trial [abstract 470]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
22. Colonno RJ, Rose R, Cianci C, et al. Emergence of atazanavir resistance and maintenance of susceptibility to other PIs is associated with an I50L substitution in protease [abstract 597]. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003.
23. Kantor R, Shafer R, Katzenstein D, et al. Resistance to reverse transcriptase and protease resistance mutations in HIV-1-infected patients on antiretroviral therapy [abstract 566]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
24. Coakley EP, Doweiko JP, Bellosillo NA, et al. HIV drug resistance profiles and clinical and virologic outcomes among HIV-infected subjects with stable detectable plasma viral loads <1000 copies/mL for at least 12 months [abstract 556]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.